Rapport Therapeutics (RAPP) Enterprise Value (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Enterprise Value of -$476.8 million for Q1 2026, down 726.18% year-over-year from $76.1 million in Q1 2025, and down 803.85% quarter-over-quarter from -$52.8 million in Q4 2025.
Rapport Therapeutics (RAPP) Enterprise Value (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Enterprise Value for 4 consecutive years, with -$476.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 726.18% year-over-year to -$476.8 million; the TTM figure through Mar 2026 stood at -$476.8 million (down 726.18% YoY), while the FY2025 annual figure was -$52.8 million, up 82.72% from the prior year.
- Enterprise Value slipped to -$476.8 million in Q1 2026 per RAPP's latest filing, from -$52.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$39.4 million in Q3 2024 and bottomed at -$513.1 million in Q3 2025.
- Historically, Enterprise Value has averaged -$200.4 million across 4 years, with a median of -$94.9 million in 2023.
- On a YoY basis, Enterprise Value climbed as much as 82.72% in 2025 and fell as far as 1201.67% in 2025.
- Rapport Therapeutics' Enterprise Value stood at -$70.3 million in 2023, then sank by 334.54% to -$305.3 million in 2024, then soared by 82.72% to -$52.8 million in 2025, then slumped by 803.85% to -$476.8 million in 2026.
- Business Quant data shows RAPP's Enterprise Value at -$476.8 million in Q1 2026, -$52.8 million in Q4 2025, and -$513.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -436.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -436.08 Mn |
| Mar 31, 2026 | -476.78 Mn |
| Dec 31, 2025 | -52.75 Mn |
| Sep 30, 2025 | -513.11 Mn |
| Jun 30, 2025 | -465.78 Mn |
| Mar 31, 2025 | -57.71 Mn |
| Dec 31, 2024 | -305.28 Mn |
| Sep 30, 2024 | -39.42 Mn |
| Jun 30, 2024 | -110.27 Mn |
| Mar 31, 2024 | -74.37 Mn |
| Dec 31, 2023 | -70.25 Mn |
| Sep 30, 2023 | -159.41 Mn |
| Jun 30, 2023 | -79.53 Mn |